Louisiana was one of 13 states that filed individual suits in state courts over allegations that Lilly pushed Zyprexa for
uses that had not been approved by federal regulators.
Eli Lilly and Co. won a U.S. court ruling Wednesday that bars Teva Pharmaceutical Industries Ltd. from selling a generic version
of the cancer drug Gemzar until November.
Eli Lilly and Co.’s Alimta has received the preliminary backing of a United Kingdom agency as a maintenance treatment for
patients with the most common form of lung cancer.
Lilly’s lobbying spending represents a 36-percent drop from the final quarter of 2008, even though the Congressional debate
over health care reform peaked during the last quarter of 2009.
Deal with unit of Massachusetts-based Thermo Fisher Scientific would keep many of the employees working in same
location.
Eli Lilly is interested in assets that may be offered for sale as a result of Sanofi-Aventis SA and Merck & Co.’s plan to
combine their veterinary units.
Indianapolis-based Eli Lilly and Co. sued rival drugmaker Hospira Inc. to prevent it from selling a generic version of the
cancer drug Gemzar before a patent on the medicine expires in 2013.
Once the nation’s wealthiest foundation, Indianapolis-based Lilly Endowment now ranks ninth among its grant-making
peers. The endowment’s value fell 15 percent last year, to an estimated $4.8 billion.
Sweeping changes phase in slowly for most, but insurers, hospitals, drug companies, employers, workers, medical device makers
and more will eventually feel impact.
Netherlands-based Synthon Pharmaceuticals is seeking U.S. Food and Drug Administration approval to sell a copy of the medicine.
Pharmaceuticals stolen Sunday morning could be worth up to $75 million.
Eli Lilly & Co., the maker of the impotence pill Cialis, bought exclusive rights from Australia’s Acrux Ltd. to
an underarm testosterone lotion called Axiron for men with limited sex drive due to low levels of the hormone.
Indianapolis-based Lilly will pay Acrux of West Melbourne, Australia, a $50 million license fee, plus $3 million when manufacturing
assets are transferred, but the deal could be worth millions more.
Regulators won’t require more time-consuming tests of the drug, but want Eli Lilly and Co. and its partners to clarify labeling,
manufacturing
processes.
The acquisition will benefit Elanco, Lilly’s animal health division in Greenfield, which has become increasingly important
to Lilly as it braces for patent-protection losses.
Brightpoint, WellPoint and Cummins are recognized by Fortune magazine as being among the best in their industries.
Lilly Endowment’s resistance to diversify its holdings reached a new height last year, as it failed to sell a single share
of the underperforming Eli Lilly and Co. stock while the broader market surged.
The former Guidant Corp. CEO and long-time Eli Lilly exec said he and his family will be returning to Indianapolis.
Drug developer Transition Therapeutics Inc. said Wednesday that it will pay $1 million to license a group of potential diabetes
drugs from Eli Lilly and Co.
With President Barack Obama looking to squeeze a bit more revenue out of the pharmaceutical industry, the stakes just keep
getting higher for Eli Lilly and Co.’s efforts to develop drugs faster and cheaper.
